Cite
Caduff N, McHugh D, Murer A, et al. Correction: Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice. PLoS Pathog. 2020;16(12):e1009167doi: 10.1371/journal.ppat.1009167.
Caduff, N., McHugh, D., Murer, A., Rämer, P., Raykova, A., Landtwing, V., Rieble, L., Keller, C. W., Prummer, M., Hoffmann, L., Lam, J. K. P., Chiang, A. K. S., Raulf, F., Azzi, T., Berger, C., Rubic-Schneider, T., Traggiai, E., Lünemann, J. D., Kammüller, M., & Münz, C. (2020). Correction: Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice. PLoS pathogens, 16(12), e1009167. https://doi.org/10.1371/journal.ppat.1009167
Caduff, Nicole, et al. "Correction: Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice." PLoS pathogens vol. 16,12 (2020): e1009167. doi: https://doi.org/10.1371/journal.ppat.1009167
Caduff N, McHugh D, Murer A, Rämer P, Raykova A, Landtwing V, Rieble L, Keller CW, Prummer M, Hoffmann L, Lam JKP, Chiang AKS, Raulf F, Azzi T, Berger C, Rubic-Schneider T, Traggiai E, Lünemann JD, Kammüller M, Münz C. Correction: Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice. PLoS Pathog. 2020 Dec 21;16(12):e1009167. doi: 10.1371/journal.ppat.1009167. eCollection 2020 Dec. PMID: 33347498; PMCID: PMC7751847.
Copy
Download .nbib
